Please use this identifier to cite or link to this item:
Title: SEOM clinical guidelines for the management of germ cell testicular cancer (2016).
Authors: Aparicio, J
Terrasa, J
Durán, I
Germà-Lluch, J R
Gironés, R
González-Billalabeitia, E
Gumà, J
Maroto, P
Pinto, A
García-Del-Muro, X
Keywords: Chemotherapy;Germ-cell tumor;Surgery;Testicular cancer
metadata.dc.subject.mesh: Adolescent
Neoplasm Staging
Neoplasms, Germ Cell and Embryonal
Practice Guidelines as Topic
Risk Factors
Testicular Neoplasms
Young Adult
Issue Date: 4-Nov-2016
Abstract: Testicular cancer represents the most common malignancy in males aged 15-34 years and is considered a model of curable neoplasm. Maintaining success, reducing treatment burden, and focusing on survivorship are then key objectives. Inguinal orchiectomy is the first recommended maneuver that has both diagnostic and therapeutic aims. Most patients are diagnosed with stage I disease (confined to the testicle). Close surveillance and selective, short-course adjuvant chemotherapy are accepted alternatives for these cases. In patients with more advanced disease (stages II and III), 3-4 courses of cisplatin-based chemotherapy (according to IGCCCG risk classification) followed by the judicious surgical removal of residual masses represent the cornerstone of therapy. Poor-risk patients and those failing a first-line therapy should be referred to specialized tertiary centers. Paclitaxel-based conventional chemotherapy and high-dose chemotherapy plus autologous hematopoietic support can cure a proportion of patients with relapsing or refractory disease.
metadata.dc.identifier.doi: 10.1007/s12094-016-1566-1
Appears in Collections:Producción 2020

Files in This Item:
File SizeFormat 
PMC5138244.pdf401,69 kBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons